Bladder leiomyoma

Summary

Bladder leiomyoma (MONDO:0001634) is a disease. A subtype of bladder benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder leiomyoma
Mondo ID	MONDO:0001634
DOID	DOID:13109
NCIT	C6178
UMLS	C1332560
MedGen	272371
Anatomy (UBERON)	UBERON:0001255
Is cancer (heuristic)	no

Also known as: bladder leiomyoma · leiomyoma of bladder · leiomyoma of the bladder · leiomyoma of the urinary bladder · leiomyoma of urinary bladder · urinary bladder leiomyoma

Disease family

This is a subtype of bladder benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign urinary system neoplasm › bladder benign neoplasm › bladder leiomyoma

Related subtypes (3): bladder squamous papilloma, nephrogenic adenoma of urinary bladder, bladder urothelial papilloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.